AVTX-801 D-galactose Supplementation in SLC35A2-CDG (NCT05402384) | Clinical Trial Compass
Not Yet RecruitingPhase 2
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
United States10 participantsStarted 2027-01
Plain-language summary
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
Who can participate
Age range1 Month
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Molecular confirmation of SLC35A2 genetic variant
* Age \> 1 month
* Presence of seizures, chronic vomiting, chronic constipation, or chronic diarrhea
* A parent or legal guardian must be available and willing to provide consent on behalf of minor subjects or adult subjects who are unable to give informed consent due to developmental disabilities.
* Use of contraception in females \> age 8 years
* Previously performed eye exam within last year
Exclusion Criteria
* Aldolase-B deficiency
* Galactosemia
* Hemolytic uremic syndrome
* Hemoglobin \< 7 mg/dL
* LFTs \> 3x ULN
* Previously experienced severe AEs from oral galactose (severe diarrhea, vomiting, constipation, galactosuria, or increased liver glycogen storage)
* Other history of galactose intolerance as determined by the investigator
* Currently treated with ketogenic diet
* Current enrollment in another trial involving investigational compounds
* Ongoing dietary D-galactose supplementation
* Use of investigational compounds
* Pregnancy